Why Smarter PBM Decisions Start With a Pharmacy Savings Analysis
By: Kevin Kobielski, President of Navion In pharmacy benefits, it’s not enough to chase better numbers—you have to understand what […]
Are GLP-1s Worth the Cost for Weight Loss? A Data-Driven Look for Payers
By Jason Peterson, RPh; Beckie Fenrick, PharmD, MBA; and Emily Crisano, PharmD, RPh As GLP-1 medications like Wegovy, Zepbound and
Why Your PBM May Be the Most Consequential Part of Your Health Plan
By Kevin Kobielski, President of Navion Ten years ago, pharmacy benefits were an important—but manageable—slice of the healthcare pie. Today,
Q2 Drug Approvals and Biosimilar Changes Impacting Your Pharmacy Strategy
The second quarter of 2025 has brought a steady flow of movement in the FDA pipeline, biosimilars gaining even more
How the 2025 American Diabetes Association Guidelines Will Impact Your Pharmacy Benefit Strategy
By Jason Peterson, RPh; Beckie Fenrick, PharmD, MBA; and Emily Crisano, PharmD, RPh The American Diabetes Association (ADA) recently released
5 Ways to Win RFP Season (Before It Even Starts)
Even the most seasoned brokers can overlook small details that make a big impact during RFP season. With timelines tightening
Weight Management Benefits: A Strategic Guide for Brokers and their Plan Sponsors
By Beckie Fenrick, PharmD, MBA; Emily Crisano, PharmD, RPh; and Jason Peterson, RPh Weight management isn’t just a personal issue—it’s
